SCSG 2 LVER SYMPOSIUM 3 DECEMBER 9-10, 2023

Updates in the Management of Portal Hypertension AASLD 2023 Guidance

Timothy Morgan, MD Chief, Hepatology, VA Long Beach Director, VA National Liver Disease Program Professor of Medicine, University of California, Irvine

AASLD Practice Guidance on Risk Stratification and Management of Portal Hypertension and Varices in Cirrhosis

Best practices for:

- Identification of portal hypertension
- <u>Prevention</u> of initial hepatic decompensation
- <u>Management</u> of acute variceal hemorrhage
- <u>Reduction</u> in risk of recurrent variceal hemorrhage
- In alignment with Baveno VII recommendations (J Hepatol 2022;76:959)

David Kaplan, Jaime Bosch, Cristina Ripoll, Maja Thiele, Brett Fortune, Douglas Simonetto, Lupe Garcia-Tsao. Hepatology. 2023 PMID: 37870298.

New Concepts

- Advanced chronic liver disease (ACLD)
- Clinically significant portal hypertension (non-invasive diagnosis)
- Carvedilol to prevent decompensation
- Further decompensation

New Concepts: Advanced Chronic Liver Disease (ACLD)

- Advanced chronic liver disease (ACLD)
 - A clinical diagnosis of cirrhosis or near cirrhosis (F3/4) based on <u>liver stiffness measurement</u>
 - Replaces liver biopsy and/or imaging (eg, US, CT, MRI) to diagnose patients at risk of complications of cirrhosis (eg, variceal bleeding, ascites, etc.)
- cACLD: *compensated* advanced chronic liver disease
 - Replaces compensated cirrhosis
- dACLD: *decompensated* advanced chronic liver disease
 - Ascites, variceal bleeding, hepatic encephalopathy, HRS-AKI, jaundice
 - Replaces decompensated cirrhosis






ACLD=Advanced Chronic Liver Disease (F3 or F4)

New Concepts: Clinically Significant Portal Hypertension (CSPH)

- Portal hypertension: WHVP ≥6 mm Hg
- Clinically significant portal hypertension (CSPH)
 - WHVP ≥10 mm Hg
 - \uparrow Risk of variceal bleeding and decompensation events
 - Non-invasive diagnosis based on liver stiffness and platelet count

Hepatic Venous Pressure Gradient Measurement




Clinically Significant Portal Hypertension is present if


- Clinical decompensation
- · Gastroesophageal varices on endoscopy
- Collaterals or hepatofugal flow on abdominal imaging

Based on liver stiffness measurement and platelet count


- LSM ≥25 kPa irrespective of platelet count
- LSM 20 24.9 kPa and platelet count <150,000/mm³
- LSM 15 19.9 kPa and platelet count <10,000/mm³



Further Decompensation: 2028 patients with first decompensation (5-year follow up)




In Cirrhosis/ACLD, There Are 3 Prognostic Stages, Each Associated With a Higher Mortality



VH=variceal hemorrhage; HE= hepatic encephalopathy.

D'Amico, Garcia-Tsao, *J Hepatol*. 2006;44:217-31; Baveno VII consensus. *J Hepatol*. 2022;76:959; D'Amico, Garcia-Tsao. *Hepatology*. [in press]. Modified from Dr. Garcia-Tsao.


The Main Driver of Decompensation Is Portal Hypertension



VH=variceal hemorrhage; HE= hepatic encephalopathy.

D'Amico, Garcia-Tsao, *J Hepatol.* 2006;44:217-31; Baveno VII consensus. *J Hepatol.* 2022;76:959; D'Amico, Garcia-Tsao. [in press]. Modified from Dr. Garcia-Tsao.

In Patients With Compensated Cirrhosis, Preventing Decompensation (Ascites, VH) Is a Loftier Goal Than Just Preventing VH



CSPH= clinically significant portal hypertension; VH = variceal hemorrhage; HE = hepatic encephalopathy; NSBB=non-selective beta-blockers. Modified from Dr. Garcia-Tsao.

NSBBs Prevented Decompensation and/or Death in Patients With Compensated Cirrhosis and WHVP≥10 mmHg (No or Small Varices)


Probability of developing any decompensation or death

Ascites, variceal hemorrhage, Overt HE, HRS-AKI

Decompensation or death

- 27% of placebo vs
- 16% of NSBB

11% reduction; NNT=9



NSBB= nonselective beta-blocker; CSPH= clinically-significant portal hypertension; HVPG= hepatic venous pressure gradient Villanueva et al (PREDESCI trial). *Lancet.* 2019;393:1597-1608.

Α

Carvedilol, Compared to Propranolol, Is More Effective in Reducing HVPG and Significantly Reduces Decompensation and Death Compared with Placebo/EVL

Study or subgroup	Carvedilol		Traditional, beta-blocker		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl	Random, 95% CI	Random, 95% CI
Bañares 2002	24	15.2 (3.9)	22	17.6 (3.4)	-	16.24%	-2.4[-4.51,-0.29]
De 2002	17	13.6 (5.4)	16	13.1 (5.3)		5.42%	0.5[-3.15,4.15]
Gupta 2016	29	12.9 (3.4)	28	13.5 (3.7)		21.21%	-0.6[-2.45,1.25]
Hobolth 2012	14	14 (4.5)	12	16.5 (4.6)	+	5.81%	-2.51[-6.04,1.02]
Kim 2016	55	13.7 (4.1)	55	16 (4.8)		25.98%	-2.3[-3.97,-0.63]
Mo 2014	48	10 (3.8)	48	12 (4.6)		25.34%	-2.02[-3.71,-0.33]
Total ***	187		181		•	100%	-1.75[-2.6,-0.89]

Analysis 1.14. Comparison 1 Carvedilol versus non-selective beta-blockers, Outcome 14 Hepatic venous pressure gradient, end of treatment (mmHg) (overall).

- Carvedilol is recommended as the preferred NSBB for the treatment of portal hypertension in patients with cirrhosis
- The recommended maintenance dosage of carvedilol is 6.25–12.5 mg/day, after initiating treatment for 2 days with only 6.25 mg at bedtime
- Maintenance dosage can be given as a single dose

Control

16(1)/26 [53]

5(4)/53 [54]

9(5)/59 [73]

4(3)/33 [90]

34(13)/171 [270] 2

Study

Tripathi 2009

Bhardwai 2017

Villanueva 2019

Shah 2014

Pooled

 In patients with concomitant arterial hypertension or cardiac disease, the dose of carvedilol may be further increased to address non-hepatic indications

 15% Cl)
 Weight (%)

 I-1.812)
 32%

 I-1.962)
 28%


 '-2.073)
 18%

 !-1.856)
 22%


 I-0.896)
 100%

Zacharias AP et al. Cochrane Database Syst Rev. 2018;10:CD011510; Villanueva et al. Baveno Cooperation meta-analysis. J Hepatol. 2022; 77:1014-25; Modified from Dr. Garcia-Tsao.


New Paradigm for cACLD and CSPH: Carvedilol to Prevent Decompensation




New Paradigm: cACLD With CSPH




New Paradigm: cACLD without CSPH




New Paradigm: cACLD without CSPH




New Paradigm: cACLD + CSPH Intolerant to NSBB



New Paradigm: FibroScan not available




In Patients With Ascites (Already Decompensated) Who Have Not Bled, The Objective Is to Prevent First Variceal Hemorrhage



Tripathi et al. Hepatology. 2009;50:825-833; McDowell et al. Aliment Pharmacol Ther. 2021;53(4):531-539.

In Patients With Variceal Hemorrhage Goals of Therapy are to Control Hemorrhage and to Prevent Recurrent Hemorrhage and Death



VH=variceal hemorrhage; HE= hepatic encephalopathy.

D'Amico, Garcia-Tsao, *J Hepatol*. 2006;44:217-31; Baveno VII consensus. *J Hepatol*. 2022;76:959; D'Amico, Garcia-Tsao. *Hepatology*. [in press]. Modified from Dr. Garcia-Tsao.

Control of Acute Variceal Hemorrhage in Patients With Cirrhosis

• IV vasoactive drug as soon as VH is suspected

- Antibiotic prophylaxis (ceftriaxone 1 g/d)
- Cautious PRBC transfusion: target Hgb 7 g/dL

Unchanged from previous guidance

- Upper endoscopy should be performed within 12 hours of presentation with AVH
- If esophageal variceal bleeding is confirmed, endoscopic variceal ligation (EVL) should be performed



 Fresh frozen plasma and platelet transfusions should not be administered based on INR or platelet count targets, respectively, because there is no evidence of benefit of such transfusions in acute variceal hemorrhage, and in the case of fresh frozen plasma, there is evidence of potential harm



 Proton pump inhibitors should be discontinued once acute variceal hemorrhage has been confirmed as the bleeding source in the absence of other specific indications



AASLD Practice Guidance on the Use of TIPS, Variceal Embolization, and Retrograde Transvenous Obliteration in the Management of Variceal Hemorrhage

Edward Wolfgang Lee¹ I Bijan Eghtesad² I Guadalupe Garcia-Tsao^{3,4} I Ziv J. Haskal⁵ I Virginia Hernandez-Gea⁶ I Hamed Jalaeian⁷ I | Sanjeeva P. Kalva⁸ I Arpan Mohanty⁹ I Dominique Thabut¹⁰ I | Juan G. Abraldes¹¹

The present document aims to equip care providers with an in-depth understanding of the use of TIPS and other variceal embolization/obliteration in the management of variceal hemorrhage. The goal is to facilitate multidisciplinary discussions between hepatologists, gastroenterologists, interventional radiologists, and surgeons in the selection of endovascular treatment for patients with variceal hemorrhage.

Hepatology. 2023 PMID: 37390489.

TIPS and Retrograde Transvenous Obliteration (RTO)

Pre-emptive TIPS: TIPS in a high-risk patient who has bleeding at endoscopy in whom banding stops the bleeding

Salvage TIPS: TIPS in a patient in whom banding is not successful (ie, continued bleeding)


Rescue TIPS: TIPS in a patient who re-bleeds following initial banding

Retrograde Transvenous Obliteration (RTO)

IR procedure to treat varices in the stomach and GI tract (eg, rectal varices)

Acute UGI bleeding in a patient with ACLD/cirrhosis

Airway protection if AMS Admit to ICU CT/MRI/US when stable Vasoactive agents (octeotride, somatastatin, terlipressin) Antibiotics (ceftriaxone 1g/d) for 5 days or discharge Transfuse to Hgb ~7 g/dL; avoid platelets or FFP



Acute UGI bleeding in a patient with ACLD/cirrhosis


Airway protection if AMS Admit to ICU CT/MRI/US when stable Vasoactive agents (octeotride, somatastatin, terlipressin) Antibiotics (ceftriaxone 1g/d) for 5 days or discharge Transfuse to Hgb ~7 g/dL; avoid platelets or FFP

CTP B 8-9

ng


EGD within 12 hours

with banding of esophageal or GOV1 varices




Covered expandable esophageal stents (where available) or balloon tamponade should be considered in patients with uncontrolled AVH as a bridge to TIPS In patients with a MELD score > 30, lactate >12 mmol/L or Child-Pugh >13 salvage/rescue TIPS should *not* be used unless TIPS is a bridge to liver transplantation in the short-term

TIPS should be considered in patients with uncontrolled AVH ("salvage" TIPS) or who rebleed despite vasoactive therapy and EVL ("rescue" TIPS).



Transjugular Intrahepatic Portosystemic Shunt (TIPS)



PTFE-coated TIPS stents should be considered standard of care

When the indication for TIPS is variceal hemorrhage, TIPS should be progressively dilated (starting at 8 mm of diameter) to the minimum diameter needed to achieve a portosystemic pressure gradient (gradient between PV and IVC) below 12 mmHg

In patients whose portosystemic pressure gradient does not decrease below 12 mmHg despite maximum dilation of TIPS (10 mm), NSBB should be added to further decrease portal pressure

Bland portal vein thrombosis does not preclude creation of a TIPS. Referral to experienced centers should be considered

In patients with large spontaneous portal systemic collaterals, collateral embolization at the time of TIPS placement may be considered since it may decrease the risk of hepatic encephalopathy

Contraindications for TIPS


Absolute

- Congestive heart failure (Stage C/D or EF <50%)
- Severe pulmonary hypertension with mPAP >45 mm Hg
- Severe uncontrolled hepatic encephalopathy
- Uncontrolled sepsis


Relative

- Balance of risks and benefits is different in uncontrolled bleeding vs. other indications
- No specific MELD threshold can be recommended to contraindicate TIPS
- Most trials in TIPS for variceal bleeding excluded patients with a Child-Pugh >13
- Patients >75 excluded from RCTs. A recent study suggests acceptable outcomes of TIPS in highly selected patients over 70 years old





Cardiofundal Varices Drain Through Gastrorenal Shunts, "Stealing" Blood From the Portal Vein into the Systemic Circulation (Decreased Flow to the Liver)




Considerations

- Location of the varices
- Anatomy of efferent and afferent vessels
- Presence of shunts
- Flow dynamics of circuit
- Splenic vein thrombosis
- Liver function (Child Pugh score)


Indication for pre-emptive TIPS and salvage/rescue TIPs are similar to EV/GOV1


GOV=gastro-oesophageal varices; IGV= isolated gastric varices Modified from Dr. Garcia-Tsao.. Gastrorenal Shunts Can Be Obliterated With Sclerosant (BRTO), Coils (CARTO) or Vascular Plugs (PARTO). Blood Flow to Liver Increases.




CARTO or PARTO have lower complication profiles compared with traditional BRTO or mBRTO and may be the preferred methods at experienced institutions

Management Algorithm for Variceal Hemorrhage From Gastrofundal Varices (GOV2 or IGV1)





Main Goals in the Management of Chronic Liver Disease Depend on Disease Stage and Type of Complication



Acute UGI bleeding in a patient with ACLD/cirrhosis

Airway protection if AMS Admit to ICU CT/MRI/US when stable Vasoactive agents (octeotride, somatastatin, terlipressin) Antibiotics (ceftriaxone 1g/d) for 5 days or discharge Transfuse to Hgb ~7 g/dL; avoid platelets or FFP

